Background: This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL). A second randomisation compared rituximab with observation post-ASCT.
introduction
Before the widespread integration of rituximab into induction therapy, high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) was a promising option for front-line therapy in patients with aggressive B-cell nonHodgkin's lymphoma (NHL). Several randomised phase III studies have shown that such an approach is beneficial in terms of progression-free survival and is superior to consolidation chemotherapy (CT) in high-risk patients [age-adjusted International Prognostic Index [1] (aa-IPI) 2 or 3] <60 years. The role of HDT plus ASCT has been extensively studied in high-risk patients who experienced a good response to induction CT [2] [3] [4] [5] [6] [7] [8] [9] [10] .
One objective of the LNH 98-3 study was to improve upon the response rate achievable with the intensive regimen of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) every 14 days, which has been extensively reported by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [11] , by using a new induction regimen which introduces etoposide and a higher dose of cyclophosphamide [doxorubicin, cyclophosphamide and etoposide (ACE)]. A phase II study [12] in relapsing or refractory aggressive lymphoma had shown that durable responses could be achieved with rituximab alone and indicated that rituximab may have a role in relapsing aggressive B-cell lymphoma and could be worth testing to increase the response rate of initial induction therapy. When the LHN98-3 study was designed, it was not known how best to incorporate rituximab in the first-line treatment of NHL, i.e. as a part of induction or later on as maintenance. Ideally, the GELA would have investigated rituximab plus ACVBP as a potentially improved induction regimen, but in the absence of availability of preliminary data for rituximab in combination with ACVBP, the ACE regimen was proposed as the investigational treatment based on promising preliminary results [13] . Doxorubicin was administered at the same dose (75 mg/m 2 ) as in ACVBP, the cyclophosphamide dose was increased (2000 instead of 1200 mg/m 2 ) and vindesine and bleomycin were omitted while etoposide was added (150 mg/m 2 for three consecutive days). To exploit the potential benefits of rituximab in this study, patients who achieved a sustained response post-HDT and ASCT were randomised (second randomisation) to receive single-agent rituximab weekly for four consecutive weeks or observation. The main objective of this part of the study was to determine whether rituximab delivered after first-line CT followed by HDT and ASCT could improve event-free survival (EFS) in patients with poor-risk aggressive B-cell NHL. At the time of the second randomisation, patients were stratified by their response to HDT + ASCT [complete response (CR) versus partial response (PR) or unconfirmed complete response (CRu)], as the quality of this response might influence the outcome.
materials and methods patients
Eligible patients were 18-60 years old and had newly diagnosed CD20+ diffuse large B-cell lymphomas (DLBCLs) or other high-grade B-cell lymphoma (initially transformed B-cell, lymphocytic, marginal zone, follicular or nonclassified high-grade lymphomas), diagnosed according to the World Health Organisation (WHO) classification. Patients were also required to have an aa-IPI score of 2 or 3. Exclusion criteria included other lymphoma diagnoses (e.g. Burkitt's lymphoma, transformed previously diagnosed low-grade lymphoma), contraindication to anthracyclines (i.e. cardiac insufficiency, left ventricular ejection fraction <50% or recent myocardial infarct) or corticosteroid treatment, serious psychosis, sepsis or uncontrolled diabetes, neutrophils <1.5 · 10 9 /l or platelets <100 · 10 9 /l not considered related to lymphoma, renal insufficiency (serum creatinine > 150 lM/l), hepatic disorders (total bilirubin > 30 mM/l or transaminases > 2.5 upper normal limit), positive serology for HIV or hepatitis B, previous organ transplant and pregnancy.
assessments
The primary study outcome parameter was EFS. An event was defined as disease progression during or after treatment, a required change in treatment regimen or death without progression. Response to treatment was classified according to the International Workshop Criteria [14] . CR required the disappearance of all clinical signs and symptoms of disease and normalisation of biochemical values. CRu included patients with a residual lymph node mass >1.5 cm in greatest transverse diameter that had regressed by >75% in the sum of the product of greatest diameters. PR was defined as a 50% decrease in the sum of the product of greatest diameters of the largest dominant nodes or nodal masses with no increase in any other nodes, liver or spleen and no new lesions. Stable disease or progressive disease required withdrawal from treatment ( Figure 1 ).
treatment
This study employed two randomisation stages (Figure 2 ). In the first randomisation (R1), eligible patients were allocated to induction therapy with ACVBP or AC/ACE (regimens are described in Table 1 Response was reassessed between days 45 and 65 (after ASCT) and patients were stratified according to their response (CR versus CRu + PR). Patients with at least a PR were eligible for second randomisation if they had a good haematological recovery (ANC ‡ 1 · 10 9 /l and platelets ‡ 100 · 10 9 /l) and adequate renal and hepatic functions. After the second randomisation (R2), patients received four doses of rituximab (375 mg/m 2 i.v.) at weekly intervals starting no later than day 65 (after ASCT) or observation alone. Patients were assessed every 6 months during the year after the end of treatment, then annually for 5 years.
statistical methods
The primary end point was EFS estimated 2 years after ASCT. EFS was measured from the date of randomisation (either first or second randomisation, depending on the comparison) to the date of the first event. Calculation of sample size was based on the primary end point. To detect a change of 15% (null hypothesis 60% and alternative hypothesis 75%), we calculated that 300 patients treated with ASCT should be randomised over 4 years and followed-up for at least 1 year, to provide the trial with 90% power at an overall 5% significance level (130 events). The trial began in October 1999. At a planned interim analysis in February 2003 (when 170 patients had been enrolled), by the data and safety monitoring committee, a total of 37 events had been observed with no significant difference in 2-year EFS between groups (rituximab 82% versus observation 72%; P = 0.14). As this number of events was lower than that expected (37 and 60 for rituximab and observation, respectively), it was considered that the study would take much longer to complete than originally anticipated. Furthermore, at that time, there was growing evidence that combining rituximab with the induction regimen might dramatically improve the efficacy of CT. Consequently, the GELA scientific committee decided to stop the study in May 2003, when a total of 269 ASCT patients had been randomised and were being followed to assess EFS. At a median follow-up of 4 years, 65 events were observed and the revised power of the study was 0.60. Survival functions were estimated by the Kaplan-Meier method and compared by log-rank test. Differences between the results of comparative tests were considered significant if the two-sided P value was <0.05. All statistical analyses were carried out using SAS 9.13 (SAS Institute Inc., Carry, NC) software.
The study was designed by the GELA scientific committee and monitored by the GELA coordinating centre that issued treatment randomisation by fax after confirmation of the patient eligibility [stratification on aa-IPI (2 versus 3) and tumour response (CR versus CRu/PR) to induction treatment (ACE versus ACVBP)]. Case report forms collected at participating centres were sent to the GELA centralised database and keyed in twice for verification. Outliers and erroneous values were checked routinely. Queries and on-site monitoring were used for final validation.
The protocol was approved by local or national ethics committees and the national regulatory agency according to the French and Belgian regulatory laws. Patients had to give written, informed consent before being randomised onto the study. The study was entered on the National Institute of Health website (NCT00169169). Table 2 . At the first randomisation, the groups receiving each type of induction therapy were well balanced.
response to induction CT and HDT
Of the 476 patients who received induction therapy, 402 (84.5%) experienced a PR or CR and were therefore eligible for HDT (Table 3) . CR (or CRu) rates to induction treatment were 63% with ACVBP and 65% with ACE. PRs were also similar in the two groups: 22% and 19%, respectively. Seventy-two patients (18%) who experienced PR or CR following induction therapy did not receive HDT, primarily as Annals of Oncology original article a result of early failure (n = 25), leukapheresis failure (n = 17) or following a serious adverse event (SAE; n = 18); six patients were excluded following histological review, five patients refused further treatment and there was one protocol violation ( Figure 1) . Overall, 402 patients completed induction, but 72 patients withdrew from the study before receiving HDT, which was administered to 330 patients. Of these, 61 were not randomised to the observation or rituximab groups following ASCT, mainly as a result of protocol violations (n = 26). Thirteen patients progressed or died (eight progressions and five deaths) during or shortly after HDT, seven patients remained with cytopenia, six patients refused treatment, four developed hepatitis and three experienced a SAE. One patient was diagnosed with peripheral T-cell lymphoma after review and one patient developed varicella zoster virus infection. Overall, 139 patients were randomised to receive rituximab (72 and 67 from the ABCVP and AC/ACE groups, respectively) and 130 to observation (66 and 64 from the ABCVP and AC/ ACE groups, respectively). At the second randomisation, 130 patients were considered in CR (without any residual disease) and 139 were in CRu or in PR.
Long-term outcome
At a median of 4 years' follow-up from the second randomisation, there was a nonsignificant trend for increased EFS in the rituximab arm {EFS 80% [95% confidence interval (CI) 72% to 86%]} compared with the observation arm [EFS 71% (95% CI 62% to 78%); P = 0.099; Figure 3] . Similarly, when patients were stratified by aa-IPI score, no statistically significant difference in EFS was observed for rituximab compared with observation (aa-IPI 2: EFS 82% and 73% for rituximab and observation, respectively; P = 0.156; aa-IPI 3: EFS 70% and 65% for rituximab and observation, respectively; P = 0.598).
The type of induction therapy received by patients had little effect on the outcome of therapy, with similar response rates from ACVBP and AC/ACE and no significant difference in overall survival (OS) at a median follow-up of 51 months (53% and 48%, respectively, P = 0.505; Figure 4) . When patients were stratified by quality of response to HDT, a statistically significant difference in EFS was identified for patients receiving rituximab (n = 70) compared with observation alone (n = 60; Figure 5 ), in patients who achieved a CR following HDT. In these patients, EFS for those who received rituximab was 86% (95% CI 75% to 92%), compared with 68% (95% CI 53% to 79%) for those who received no consolidation (P = 0.023). However, for patients who 131 (28) 63 (24) 33 (24) 30 (24) aa-IPI score, n (%) 1 (low-intermediate) 11 (2) 3 (1) 1 (1) 2 (2) 2 (high-intermediate) 326 (69) 202 (75) 108 (78) 94 (74) 3 (high) 138 (29) 64 (24) 30 (22) Annals of Oncology original article experienced a CRu or PR following HDT, no such difference was apparent; EFS was 74% (95% CI 62% to 83%) and 73% (95% CI 61% to 82%) for patients receiving rituximab (n = 69) and observation only (n = 70), respectively (P = 0.91).
safety and tolerability
The incidence of grade 3 and 4 adverse events during induction therapy was largely similar for patients receiving ACVBP and AC/ACE for liver, cardiac, neurological, renal and lung events (all £3% of patients for any individual cycle). There was a slightly higher incidence of infection and mucositis events in patients who received AC/ACE compared with ACVBP during each cycle of induction. The incidence of grade 3 or 4 infection during cycles 1-4 was 5%, 3%, 5% and 3% for ACVBP and 8%, 9%, 8% and 9% for AC/ACE, respectively. Similarly, the incidence of grade 3 or 4 mucositis during cycles 1-4 was 3%, 7%, 5% and 4% for ACVBP and 3%, 9%, 10% and 12% for AC/ACE, respectively. Rituximab therapy was well tolerated. The 139 patients randomised to receive rituximab received 545 infusions in total. Among this group, there were eight cases of neutropenia (6%; four grade 3 and four grade 4), three of thrombocytopenia (2%; all grade 3) and two of Herpes zoster infection (1%). Prophylactic treatment of infections was not reported, and infections were only recorded if reported as SAEs.
discussion
The main objective of the study was to determine whether rituximab delivered after first-line CT followed by HDT and 
B)
CRu or PR Figure 5 . Event-free survival (EFS) by response to high-dose therapy (HDT) (A) patients in complete response (CR); (B) patients in unconfirmed complete response (CRu) or partial response (PR). In this planned subgroup analysis, there was a significant improvement in EFS for patients who experienced a CR following autologous stem-cell transplantation and received maintenance rituximab compared with those who received observation only.
original article Annals of Oncology ASCT could improve EFS in patients with poor-risk aggressive B-cell NHL, and the study was powered to detect a 15% difference at 2 years (75% versus 60%). Other end points included response rate to induction treatment, response rate at the end of treatment, survival and safety.
At a median follow-up of 4 years after the second randomisation, rituximab given weekly for four consecutive weeks after HDT and ASCT did not significantly increase EFS but there was a trend towards improvement with rituximab (EFS 80% and 71% with and without rituximab, respectively; P = 0.10).
A planned subgroup analysis of EFS according to post-HDT response showed that rituximab significantly prolonged EFS for patients who achieved a CR, but not for patients who had CRu or PR. Although the findings of subgroup analyses are generally less robust than those of the main analysis, this result is of clinical importance and is reinforced by the fact that patients were intentionally stratified by response to HDT at the time of the second randomisation.
The intensified ACE induction regimen, with the addition of an even higher dose of etoposide (450 mg/m 2 ) than the German high-grade lymphoma study group's cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone regimen (300 mg/m 2 ) [14, 15] , did not provide a significant improvement in response rate over ACVBP (63% and 65%, respectively), with a trend towards higher toxicity with ACE. Furthermore, the type of induction regimen had no effect on EFS, and overall the two induction regimens appear to be equivalent.
Data on rituximab maintenance in DLBCL during first-line treatment are very limited. In the Eastern Cooperative Oncology Group 4494 phase III trial [16] , which compared induction with combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or R-CHOP (with rituximab administered twice before cycles 1 and 2 and 2-3 days before cycles 3 and 5) with a second randomisation to rituximab maintenance (4-weekly infusion every 6 months for a total of 2 years) versus observation, rituximab maintenance showed a statistically significant benefit in EFS over observation. This effect was limited to those patients who received CHOP as induction regimen. Moreover, in the light of superior results achieved in the R-CHOP GELA study [17] with eight infusions of rituximab in elderly patients, the induction schedule used in the EGOG study may not have been adequate. CT plus rituximab is also effective in younger patients (<60 years with low-risk DLBCL), as recently demonstrated in the MabThera International Trial [18] .
Despite dramatic advances in treating DLBCL, patients with poor prognoses still exist; progression-free survival after 7 years in the GELA R-CHOP study was <50% for high-risk patients. The use of the aa-IPI score in patients who received R-CHOP does not appear to be sufficiently accurate to discriminate among groups of patients with poor prognoses [19] . The identification of patients with the highest risk disease may therefore require the assessment of new disease markers including an increased use of phenotyping and genotyping to better characterise DLBCL [20] [21] [22] . There is a need for further increasing the response rate and the quality of response, as the EFS at 4 years for patients with poor-prognosis aggressive highgrade NHL is still quite low; increasing the rate and quality of responses (with more true CRs) at induction is of paramount importance and more effective induction regimens are needed to improve prognoses for patients. To this end, the addition of rituximab to dose-intensified CT such as ACVBP followed by ASCT appears to increase progression-free survival and OS in young patients with poor-risk lymphoma [23] . Others have recently published encouraging results using the same approach [24] [25] [26] [27] . Moreover, we and others [28] [29] [30] have also demonstrated the value of a good response as assessed by positron emission tomography (PET) imaging to guide therapy decisions and identify patients early for whom HDT and ASCT is the best potential option early on. This approach is also under evaluation by GELA in the ongoing protocol for poorprognosis DLBCL.
This study reported a nonsignificant trend towards better 4-year EFS in patients who received rituximab for 4 weeks after induction CT followed by HDT and ASCT. A significant benefit of the addition of rituximab was reported in patients who achieved a true CR after HDT and ASCT compared with those who experienced a lesser response, showing the importance of the quality of response after induction treatment to long-term prognosis.
In the time since the inception of this study, the treatment of DLBCL has changed, with rituximab CT considered to be the standard induction regimen, the evaluation of response by PET scan [31] as a guide to subsequent therapy decisions and the identification of patients with poor prognosis via genetic, tumour and peripheral blood phenotype (as with some of the patients in the present study [32] ). These data emphasise the importance of achieving a true CR to the long-term prognosis of the patient, and the challenge to increase the proportion of such responses to induction therapy remains. However, the maintenance of a true CR is also a pressing issue, and these data indicate that rituximab may have a role in this respect for some patients. Maintenance therapy with rituximab has been investigated in follicular lymphoma (the primary maintenance study) and is under investigation in mantle cell lymphoma; further investigation of this strategy, using modern induction regimens, is now warranted in DLBCL. We also gratefully thank Antoine Allain, Jean Baptiste Golfier and Nicolas Nio for their determinant help in data management and Marion Fournier for statistical analyses. We also thank all the pathologists involved in the study for pathological review, especially Josette Brière, Thierry Molina and Philippe Gaulard. The authors also wish to thank Christine Wilkinson-Blanc and Martin Quinn of Prism Ideas, Ltd who provided editorial assistance. We would like to dedicate special thanks to Felix Reyes, deceased in August 2006, for his help in launching this study.
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